{"id":"W4388848431","doi":"10.1016/j.ejca.2023.113458","title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Novartis Pharmaceuticals UK Limited; Chugai Pharmaceutical; Italfarmaco; Bristol-Myers Squibb; AstraZeneca; Symphogen; Sun Pharma; Eisai; Sanofi; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Daiichi-Sankyo","keywords":"Medicine; Rash; Nausea; KRAS; Adverse effect; Internal medicine; Gastroenterology; Dysgeusia; Pharmacology; Oncology; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008890514,0.0008284694,0.001485091,0.0002108905,0.0004680271,0.0008322175,0.0003046296,0.000762198,0.003467409],"category_scores_gemma":[0.0006496509,0.0003370444,0.001346107,0.0002061634,0.0006980916,0.0007279838,0.0002288579,0.001844238,0.0007134927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007622017,"about_ca_system_score_gemma":0.0009058358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001624443,"about_ca_topic_score_gemma":0.00289554,"domain_scores_codex":[0.9996581,0.00009223536,0.00001564736,0.0000835851,0.00003298761,0.0001174632],"domain_scores_gemma":[0.9995882,0.00007931908,0.00006067701,0.00006770301,0.00003285195,0.0001712769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6866522,0.03594603,0.09741629,0.0006369518,0.004391456,0.001689245,0.0003546202,0.001581717,0.05716557,0.0003634602,0.004848339,0.1089542],"study_design_scores_gemma":[0.05298212,0.6952991,0.2010359,0.00009102008,0.004132852,0.002664044,0.0005150461,0.002094746,0.02330229,0.0004988033,0.01727009,0.0001139751],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994249,0.002058477,0.0004191272,0.0001194713,0.00007900736,0.0002093969,0.001091854,0.00003719377,0.001736439],"genre_scores_gemma":[0.9946109,0.0009234987,0.0003038048,0.000268935,0.00007362355,0.0001392786,0.001709645,0.00001339162,0.001956814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003467409,"threshold_uncertainty_score":0.01159966,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01382222958330516,"score_gpt":0.2650397317540292,"score_spread":0.2512175021707241,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}